secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001493152-22-035944
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown
--------------------------------------------------------------------------------

- Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).
- In glioma patients treated with TMZ, reduced TGF-β2 improved OS from 25 to 94 mos (N=230, p<0.0001).
- Similar OS improvement from 25 to 94 mos with radiation therapy (N=293, p<0.0001).
- Company states failure of GSK's bintrafusp alfa (TGF-β1 trap) validates focus on TGF-β2 isoform.
- Data presented at AACR-JCA Joint Conference Dec 10-14, 2022 in Maui.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/0001493152-22-035944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer